BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11949823)

  • 1. Proliferation- and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis.
    Verstegen MJ; Leenstra DT; Ijlst-Keizers H; Bosch DA
    J Neurooncol; 2002 Jan; 56(1):21-8. PubMed ID: 11949823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
    Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
    Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
    Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
    Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ependymomas: MIB-1 proliferation index and survival.
    Ritter AM; Hess KR; McLendon RE; Langford LA
    J Neurooncol; 1998 Oct; 40(1):51-7. PubMed ID: 9874186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors.
    Zamecnik J; Snuderl M; Eckschlager T; Chanova M; Hladikova M; Tichy M; Kodet R
    Mod Pathol; 2003 Oct; 16(10):980-91. PubMed ID: 14559980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry.
    Prayson RA
    Ann Diagn Pathol; 1999 Feb; 3(1):11-8. PubMed ID: 9990108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
    Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
    Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of cell cycle/apoptosis regulators and epidermal growth factor receptor in pediatric intracranial ependymomas.
    Alexiou GA; Stefanaki K; Moschovi M; Patereli A; Prodromou N; Karentzou O
    J Child Neurol; 2011 Feb; 26(2):195-8. PubMed ID: 20713981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of apoptosis in the prognosis of oligodendrogliomas.
    Schiffer D; Dutto A; Cavalla P; Chiò A; Migheli A; Piva R
    Neurochem Int; 1997 Aug; 31(2):245-50. PubMed ID: 9220457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
    Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
    Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
    Borre M; Stausbol-Gron B; Overgaard J
    J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of apoptosis and proliferation in germinoma and glioblastoma.
    Mizoguchi M; Inamura T; Shono T; Ikezaki K; Inoha S; Ohgami S; Fukui M
    Neuro Oncol; 2000 Apr; 2(2):96-102. PubMed ID: 11303626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
    Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G
    Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
    Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
    Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
    Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
    Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.